# Sabra Health Care REIT, Inc.: overview

SBRA · Nasdaq · CIK 1492298 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sbra.md) · [Financials](/companies/sbra/financials.md) · [Filings](/companies/sbra/filings.md) · [Insiders](/companies/sbra/insiders.md)

Latest reported revenue: [$128.8m](/filings/0001492298-26-000028.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001492298-26-000028).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [73.7](/filings/0001492298-25-000039.md) | [76.9 d](/filings/0001492298-26-000008.md) | [77.4](/filings/0001492298-26-000012.md) | [79.0](/filings/0001492298-26-000028.md) | [92.0](/filings/0001492298-25-000039.md) | [108 d](/filings/0001492298-26-000008.md) | [117](/filings/0001492298-26-000012.md) | [129](/filings/0001492298-26-000028.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [40.4%](/filings/0001492298-25-000039.md) | [60.7% d](/filings/0001492298-26-000008.md) | [52.0%](/filings/0001492298-26-000012.md) | [83.0%](/filings/0001492298-26-000028.md) | [24.5%](/filings/0001492298-25-000039.md) | [25.1% d](/filings/0001492298-26-000008.md) | [35.0%](/filings/0001492298-26-000012.md) | [(19.6%)](/filings/0001492298-26-000028.md) |
| Diluted EPS | $ per share | [0.13](/filings/0001492298-25-000039.md) | not reported | [0.17](/filings/0001492298-26-000012.md) | [0.27](/filings/0001492298-26-000028.md) | [0.09](/filings/0001492298-25-000039.md) | not reported | [0.16](/filings/0001492298-26-000012.md) | [(0.10)](/filings/0001492298-26-000028.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [156](/filings/0001492298-24-000008.md) | [187](/filings/0001492298-25-000008.md) | [236](/filings/0001492298-26-000008.md) | [285](/filings/0001492298-26-000008.md) | [357](/filings/0001492298-26-000008.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(72.8%)](/filings/0001492298-24-000008.md) | [(41.6%)](/filings/0001492298-25-000008.md) | [5.8%](/filings/0001492298-26-000008.md) | [44.5%](/filings/0001492298-26-000008.md) | [43.6%](/filings/0001492298-26-000008.md) |
| Diluted EPS | $ per share | [(0.52)](/filings/0001492298-24-000008.md) | [(0.34)](/filings/0001492298-25-000008.md) | [0.06](/filings/0001492298-26-000008.md) | [0.54](/filings/0001492298-26-000008.md) | [0.64](/filings/0001492298-26-000008.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sbra/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $811.9m | 41,614,351 |  | Added +2,515,962 |
| [PRINCIPAL FINANCIAL GROUP INC](/funds/1126328.md) | 2026-06-30 | $482.0m | 24,706,070 |  | Reduced −346,051 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $455.6m | 23,352,373 |  | Added +209,125 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $240.1m | 12,305,655 |  | Added +205,704 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $221.4m | 11,349,125 |  | Added +118,377 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $154.3m | 7,909,172 |  | Added +458,403 |
| [CENTERSQUARE INVESTMENT MANAGEMENT LLC](/funds/1725296.md) | 2026-06-30 | $113.4m | 5,814,427 |  | Added +1,936,617 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $103.4m | 5,300,762 |  | Reduced −108,399 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $94.4m | 4,840,401 |  | Added +67,098 |
| [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $87.1m | 4,464,764 |  | Reduced −2,208,520 |

## Recent filings

[All 1,573 filings](/companies/sbra/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-03 | 16:06 ET | [10-Q](/filings/0001492298-26-000028.md) | Quarterly report, period 2026-06-30 | 0001492298-26-000028 |
| 2026-08-03 | 16:05 ET | [8-K](/filings/0001492298-26-000027.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001492298-26-000027 |
| 2026-07-21 | 09:05 ET | [8-K](/filings/0001492298-26-000023.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001492298-26-000023 |
| 2026-06-17 | 16:40 ET | [8-K](/filings/0001492298-26-000019.md) | 5.07 Shareholder vote results | 0001492298-26-000019 |
| 2026-05-28 | 16:05 ET | [8-K](/filings/0001492298-26-000014.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001492298-26-000014 |
| 2026-04-29 | 16:06 ET | [10-Q](/filings/0001492298-26-000012.md) | Quarterly report, period 2026-03-31 | 0001492298-26-000012 |
| 2026-04-29 | 16:05 ET | [8-K](/filings/0001492298-26-000011.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001492298-26-000011 |
| 2026-04-24 | 09:06 ET | [DEF 14A](/filings/0001193125-26-175398.md) | Proxy statement, period 2026-06-17 | 0001193125-26-175398 |
| 2026-02-12 | 16:07 ET | [10-K](/filings/0001492298-26-000008.md) | Annual report, period 2025-12-31 | 0001492298-26-000008 |
| 2026-02-12 | 16:05 ET | [8-K](/filings/0001492298-26-000007.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001492298-26-000007 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001492298-26-000008.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b6965ced-5b29-4d3a-872e-4568422caefb)

## About the filer

- CIK: 1492298
- Tickers: SBRA
- Exchange: Nasdaq
- SIC code: 6798 Real Estate Investment Trusts
- State of incorporation: MD
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.